Back to Journals » OncoTargets and Therapy » Volume 10

Panel of seven long noncoding RNA as a candidate prognostic biomarker for ovarian cancer

Authors Zhan XH, Dong C, Liu G, Li YX, Liu L

Received 26 November 2016

Accepted for publication 28 December 2016

Published 1 June 2017 Volume 2017:10 Pages 2805—2813

DOI https://doi.org/10.2147/OTT.S128797

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Dr Tohru Yamada

Xiaohui Zhan,1,2 Chuanpeng Dong,3 Gang Liu,3 Yixue Li,1,2,4 Lei Liu3

1Key Lab of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 2University of Chinese Academy of Sciences, Beijing, 3Institute of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 4Shanghai Center for Bioinformation Technology, Shanghai Industrial Technology Institute, Shanghai, People’s Republic of China

Abstract: Ovarian cancer is one of the most common and lethal gynecological malignancies. The diagnosis of ovarian cancer is often at an advanced stage. Accumulated evidence suggests that long noncoding RNAs (lncRNAs) play important roles during ovarian tumorigenesis. In this study, using the lncRNA-mining approach, we analyzed lncRNA expression profiles of 493 ovarian cancer patients from Gene Expression Omnibus datasets, and identified a signature group of seven lncRNAs (BC037530, AK021924, AK094536, AK094536, BC062365, BC004123 and BC007937) associated with patient survival in the training dataset GSE9891. We also formulated a risk score model to divide patients into low-risk and high-risk groups based on the expression of these seven lncRNAs. We further validated the predictive power of our risk score model in two other datasets, GSE26193 and GSE63885. Our analysis showed that the seven-lncRNA signature can serve as an independent predictor apart from Federation of Gynecology and Obstetrics (FIGO) stage and patient age. Further investigation revealed the seven-lncRNA signature correlated with few critical signaling pathways involved in cancer. Combined, all these findings strongly support that the seven-lncRNA signature can serve as a strong prognosis biomarker.

Keywords: lncRNA, ovarian cancer, prognostic, gene signature, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]